https://techpapersworld.com/wp-content/uploads/2022/09/XNK-Therapeutics-appoints-Dr.-Anna-1280x720.jpg

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17th. She will be a member of the company’s management team. Anna-Karin Maltais, PhD, will be responsible for further developing and implementing XNK Therapeutics’ scientific strategy. She will lead a team responsible for research and innovation with focus on continuing the development of the company’s platform as well as improving the production processes and executing operational research plans. Dr. Maltais...